Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease, Diabetes Mellitus
Efficacy and Safety of Coronary Amphilimus-ELuting Stent in diAbeTic patiEnts
More recently a polymer-free drug eluting stent (Amphilimus eluting stent) has shown to have a superiority in terms of efficacy and safety if compared with stable polymer drug eluting stent when used in diabetic patients.
- Trial name
- ESCALATE (NCT03651180)
- Where
- Italy
- Volunteers
- 3,400 people
- Sponsor
- Ospedale S. Giovanni Bosco
Coronary Artery Disease
Xience or Vision Stent Management of Angina in the Elderly
The treatment of complex coronary disease causing limiting symptoms of angina with drug-eluting stent technology will prove superior to bare metal stent technology, with respect to a combined endpoint of mortality, MI…
- Trial name
- XIMA (NCT02198716)
- Testing
- Percutaneous Coronary Intervention using drug eluting stents, Percutaneous Coronary Intervention using bare metal stents
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Brighton and Sussex University Hospitals NHS Trust
Vascular Disease, Myocardial Ischemia
A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population
The purpose of this study is to evaluate the safety and effectiveness of the AVJ-09-385 Small Vessel Everolimus Eluting Coronary Stent System (EECSS) (2.25 mm diameter stent) in treatment of subjects with ischemic heart disease…
- Conditions
- Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease
- Trial name
- SV JAPAN (NCT01115933)
- Testing
- XIENCE PRIME SV EECSS
- Where
- 14 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Procedural Advantages of a Novel Drug-Eluting Coronary Stent
This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.
- Trial name
- NCT02881216
- Testing
- Synergy Stent, Currently common drug-eluting stent (DES)
- Volunteers
- 814 people
- Sponsor
- University Hospital Heidelberg
Coronary Artery Disease
Tryton Post Approval Study (PAS) for the Tryton Side Branch Stent
TRYTON Post Approval Study (PAS) of the Tryton Side Branch Stent
- Trial name
- PAS (NCT03318796)
- Testing
- Coronary Artery Stenting
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Tryton Medical, Inc.
Coronary Artery Disease
Prevail Global Study
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
- Trial name
- NCT06535854
- Testing
- Prevail DCB, Agent DCB
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 1,205 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
This study is a prospective, multi-center single arm registry trial, planning to enroll 785 subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year after index procedure.
- Trial name
- NCT04179045
- Testing
- The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Where
- 5 sites in China
- Volunteers
- 785 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Renal Artery Stenosis, Left Ventricular Hypertrophy
Stenting of Renal Artery Stenosis in Coronary Artery Disease Study
The Stenting of Renal Artery Stenosis in Coronary Artery Disease (RASCAD) study is a randomized controlled trial designed to evaluate the effect of renal artery stenting+medical therapy versus medical therapy alone on left…
- Trial name
- RASCAD (NCT01173666)
- Testing
- stenting angioplasty plus medical therapy, Medical therapy
- Where
- Italy
- Volunteers
- 168 people
- Sponsor
- Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele
Coronary Artery Disease
Predictors and Outcomes of Occlusion of Jailed Side Branches Following Main Vessel Coronary Artery Stenting
Assessment of possible predictors of occlusion of jailed side branches following main vessel coronary artery stenting and detection of clinical, electrocardiographic and echocardiographic changes following occlusion of jailed…
- Trial name
- NCT04581837
- Testing
- 2D-speckle tracking echocardiography
- Volunteers
- 60 people
- Sponsor
- Assiut University
Coronary Artery Disease
Safety and Efficacy of POT PTCA Balloon Dilatation Catheter for the Optimal Dilation After DES Implantation
The objective of this randomized control trial is to gain clinical insight on the use of POT PTCA balloon dilatation catheter for the optimal dilation after drug-eluting stent implantation.
- Trial name
- POT-DES (NCT05368129)
- Testing
- Balloon dilation
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Coronary Artery Disease, Myocardial Ischemia
Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)
The purpose of this study is to evaluate the safety and performance of a new version of a coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- RENASCENT III (NCT02900937)
- Testing
- AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 13 sites in Colombia, Italy
- Volunteers
- 70 people
- Sponsor
- Amaranth Medical Inc.
Coronary Artery Disease
The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.
The main objective of this study is to assess the effectiveness of the CYPHER™ (sirolimus-eluting) stent in reducing in-lesion late lumen loss in de novo native coronary artery lesions in small vessels (2.25 - 2.75 mm) as…
- Trial name
- SVELTE (NCT00235066)
- Testing
- PCI
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions
1.) Indigenously developed and designed BioMimeTM is a predictably safe \& efficacious 3rd generation drug eluting stent (DES) with a propensity to minimize vascular injury by use of an intelligent mix of ultra-low strut…
- Trial name
- meriT-1 (NCT01507519)
- Testing
- Sirolimus Eluting Coronary Stent System (Biomime)
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Coronary Artery Disease
The Nordic Bifurcation Study III
Should we, or should we not, perform dilatation of the side branch through the main vessel stent, if there is acceptable blood flow in the side branch?
- Trial name
- BIF III (NCT00914199)
- Testing
- Percutaneous coronary intervention (PCI)
- Where
- Denmark
- Volunteers
- 477 people
- Sponsor
- Evald Hoej Christiansen
Coronary Artery Disease, Acute Coronary Syndrome
Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerosis
The objectives of this study are 1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Resolute Onyx™ stent. 2.
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Angina Pectoris
- Trial name
- HOST-ONYX (NCT03151018)
- Testing
- Resolute Onyx
- Where
- 16 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent in the Treatment of Long Diffuse Coronary Artery Disease
An observational study to evaluate safety and efficacy of the hybrid approach DES/DCB in the treatment of long diffuse de novo coronary artery disease
- Trial name
- HYPER II (NCT05650450)
- Testing
- DES+DCB
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Percutaneous Coronary Intervention (PCI), Coronary Artery Disease (CAD)
Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent
Randomized, open-label, single-center, non-inferiority clinical trial to compare late lumen loss (LLL) at 12 months in Tunisian population undergoing coronary percutaneous intervention between Drug Eluting Balloon treated group…
- Conditions
- Percutaneous Coronary Intervention (PCI), Coronary Artery Disease (CAD), De Novo Stenosis
- Trial name
- DEBATE (NCT05516446)
- Testing
- DEB for de Novo Lesions, DES for de Novo Lesions
- Where
- Tunisia
- Volunteers
- 290 people
- Sponsor
- General Administration of Military Health, Tunisia
Coronary Artery Disease
Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting
The aim of the current study is to compare the antiplatelet efficacy and safety of clopidogrel napadisilate and clopidogrel bisulfate in Coronary Artery Disease (CAD) patients after coronary stent implantation.
- Trial name
- NCT01584791
- Testing
- clopidogrel napadisilate + aspirin, clopidogrel bisulfate + aspirin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Seoul National University Hospital
Acute Coronary Syndrome, Angina Pectoris
Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- BIO-RESORT (NCT01674803)
- Testing
- Orsiro, Synergy, Resolute Integrity
- Where
- Netherlands
- Volunteers
- 3,514 people
- Sponsor
- Foundation of Cardiovascular Research and Education Enschede
Coronary Artery Disease
PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis
The purpose of this study is to investigate the prognostic values of 2-dimensional residual disease patterns determined by quantitative flow ratio (QFR) pullbacks after stent implantation.
- Trial name
- CHART-OPTIMIZE (NCT05125107)
- Testing
- Quantitative Flow Ratio derived PPG and dQFR/ds
- Volunteers
- 1,607 people
- Sponsor
- Shanghai Zhongshan Hospital